A Deeper Dive Into Design Therapeutics
Larimar Therapeutics Inc LRMR
$3.82
▼ -0.13%
($-0.01)
🗓️ Earnings Next Week
Open
$3.82
Prev Close
$3.83
Day Range
$3.72 – $3.86
52W Range
$2.72 – $6.42
Market Cap
$396.83M
Beta
0.77
EPS (TTM)
$-2.08
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-06-19 |
| Shares Out. | 103,880,000 |
| Website | larimartx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 71 |
| Net Income | -$29.6M |
| Free Cash Flow | -$131.3M |
| Total Assets | $208.5M |
| Total Liabilities | $50.5M |
| Equity | $158.0M |
About Larimar Therapeutics Inc
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Larimar Therapeutics Inc is a publicly traded company under the ticker symbol LRMR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-07-01)